Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04102618
Title A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1)
Recruitment Terminated
Gender female
Phase Phase I
Variant Requirements No
Sponsors Oncolytics Biotech

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Her2-receptor positive breast cancer


Atezolizumab + Pelareorep

Atezolizumab + Pelareorep + Trastuzumab

Letrozole + Pelareorep

Atezolizumab + Letrozole + Pelareorep

Age Groups: senior | adult
Covered Countries ESP

No variant requirements are available.